Positives

• Per the ANIBAL protocol review, dabigatran has shown a good efficacy and safety profile in COVID-19 patients with a lower risk of hepatotoxicity than other anticoagulants and minimal CYP3A4 interaction PMC.
  
  

Negatives

• Long COVID microclot research has used apixaban as the DOAC of choice in the well-known triple-therapy series, leaving dabigatran without direct PASC outcome data Medhelpclinics.
  
  

Hurdles & Side Effects

• Dabigatran (Pradaxa) twice-daily dosing without routine monitoring is convenient but the GI side effects (dyspepsia, gastritis) cause many patients to discontinue, and bleeding events require the costly idarucizumab reversal agent Hematology.